Furthermore, combined therapy of celecoxib with other metabolic agents (e.g., AMP‐activated protein kinase activator metformin) should be evaluated to confirm the validity of COX‐2 inhibitors in the treatment of NAFLD. This evidence concerns the gene PTGS2 and metabolic dysfunction-associated steatotic liver disease.